louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03223285: Diaphragm's Manual Therapy in Patients With Chronic Neck Pain
Official title: Diaphragm's Manual Therapy Reduce Pain in Patients With Chronic Neck Pain: a Randomised Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Neck Pain
Keywords: Cervical spine;
Diaphragm;
Manual Therapy
Pain
Range of Motion
Lead sponsor: Università degli Studi di Ferrara
Sponsor class: OTHER
First posted: 2017-07-21
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this study is to evaluate the effect of diaphragm's manual therapy in addition to cervical spine manual therapy in terms of pain, cervical spine range of motion, trigger points pain pressure threshold, disability and quality of life in patient with chronic aspecific neck pain.


Eligibility criteria: Inclusion Criteria:

* Neck pain since at least 3 months
* Age \> 18 years and \< 65 years
* Male or Female

Exclusion Criteria:

* Pregnancy
* Contraindications for manual therapy or inability to complete the treatment
* Patients who received a physiotherapy or osteopathic treatment during the last 3 months
* Medical diagnosis of rheumatologic disease
* Medical diagnosis of respiratory disease (COPD, asthma)
* Spine surgery
* Medical diagnosis of past or present cancer
* Thoracic or abdominal surgery in the last 3 years
* Whiplash injuries
* Previous cervical fracture
* Cervical anatomical changes
* Thrombotic events
* Body temperature greater than 37 degrees in the previous 48 hours
* Obesity (BMI greater than 30)

Primary outcomes:
measure: Change in Numeric Pain Rating Scale (NPRS)
timeFrame: Week 0, 1, 2, 3, 13, 25
Secondary outcomes:
measure: Change in Range of motion (ROM)
timeFrame: Week 0, 1, 2, 3, 13, 25
measure: Change in Pain pressure threshold
timeFrame: Week 0, 1, 2, 3, 13, 25
measure: Change in Neck Disability Index (NDI)
timeFrame: Week 0, 3, 13, 25
measure: Change in Medical outcomes study short form 36 (SF-36)
timeFrame: Week 0, 3, 13, 25
measure: Adverse events
timeFrame: Week 2, 3, 13, 25
Other outcomes:
Locations:
city: Ferrara
country: Italy
facility: Fisiotech - Studio Associato di Fisioterapia
Study officials:
affiliation: Università degli Studi di Ferrara, Physiotherapy Degree Course
name: Marco Da Roit, PT, MSc
role: PRINCIPAL_INVESTIGATOR
affiliation: Università degli Studi di Ferrara, Physiotherapy Degree Course
name: Giulia Simoni, PT, OMT, MSc
role: PRINCIPAL_INVESTIGATOR
References:
citation: Simoni G, Bozzolan M, Bonnini S, Grassi A, Zucchini A, Mazzanti C, Oliva D, Caterino F, Gallo A, Da Roit M. Effectiveness of standard cervical physiotherapy plus diaphragm manual therapy on pain in patients with chronic neck pain: A randomized controlled trial. J Bodyw Mov Ther. 2021 Apr;26:481-491. doi: 10.1016/j.jbmt.2020.12.032. Epub 2021 Feb 16.
Clinical trial NCT01833585: Treatment of Chronic Critical Limb Ischemia With G-CSF-mobilized Autologous Peripheral Blood Mononuclear Cells
Official title: Pilot Study of Treatment of Chronic Critical Limb Ischemia With G-CSF-mobilized Autologous Peripheral Blood Mononuclear Cells
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Critical Limb Ischemia
Atherosclerosis
Ischemic Ulcer
Gangrene
Keywords: critical limb ischemia
atherosclerosis
ischemic ulcer
rest pain
gangrene
Lead sponsor: Mahidol University
Sponsor class: OTHER
First posted: 2013-04-17
Enrollment: 8
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine the safety and efficacy of G-CSF-mobilized autologous peripheral blood mononuclear cell injection to ischemic limbs of patients with critical limb ischemia.


Eligibility criteria: Inclusion Criteria:

* Patients with critical limb ischemia confirmed by toe pressure, ABI, TCOM
* Levels of arterial occlusion are femoropopliteal or tibioperoneal occlusion
* Poor distal artery runoff
* Age 18-70 year

Exclusion Criteria:

* Planned for major amputation within 4 weeks
* Receive blood component within 4 weeks
* Acute myocardial infarction
* severe valvular heart disease
* renal failure
* liver failure
* Cancer
* Hypercoagulable state
* Severe infection
* Pregnancy

Primary outcomes:
measure: Number of patients without major amputation after mononuclear cell injection
timeFrame: 3 month
Secondary outcomes:
Other outcomes:
Locations:
city: Bangkoknoi
country: Thailand
facility: Vascular Surgery, Siriraj Hospital, Mahidol University
state: Bangkok
Study officials:
affiliation: Mahidol University
name: Nuttawut Sermsathanasawadi, MD.,Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01459185: A Feasibility Study of Oral Adjuvant Chemotherapy With S-1
Official title: A Feasibility Study of Adjuvant Chemotherapy With Oral Fluoropyrimidine S-1 for Non-small Cell Lung Cancer
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Non-small Cell Lung Cancer
Keywords: Non-small cell lung cancer
Adjuvant chemotherapy
oral fluoropyrimidine
S-1
Feasibility study
Surgery
Lead sponsor: Nagasaki University
Sponsor class: OTHER
First posted: 2011-10-25
Enrollment: 55
Sex: ALL
Minimum age (years): 20
Maximum age (years): 79
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The investigators confirm the feasibility of 1-year administration of oral fluoropyrimidine S-1 as an adjuvant chemotherapy for the patient who received complete resection of non-small cell lung cancer. The investigators presume they can achieve high completion rate with low toxicity.

Detailed description: Chemotherapy comprised eight courses (4-week administration, 2-week withdrawal) of S-1 (FT, gineracil, oteracil potassium; Taiho Pharmaceutical, Tokyo, Japan) at 80-120 mg/body/day according to body surface area (BSA): BSA \<1.25 m2, 80 mg/day; BSA \>1.25 m2 but \<1.5 m2, 100 mg/day; and BSA \>1.5 m2, 120 mg/day. S-1 was administered orally, twice daily after meals, starting within 4 weeks after surgery.

Eligibility criteria: Inclusion Criteria:

1. NSCLC with histological proof.
2. Pathological stage IB, II, or IIIA NSCLC (fifth edition of UICC/AJCC 1997) after complete resection.
3. No prior treatment except for surgery.
4. Sufficient oral intake.
5. Performance status (PS) 0 or 1.
6. Patients also had to have adequate organ function (3500 \<leukocytes \< 12,000/mm3; thrombocytes, \>100,000/mm3; total bilirubin,\<1.5 mg/dl; AST and ALT, less than twice the normal limits at each institution; BUN, \<25 mg/dl; creatinine, less than the normal limits at each institution; and creatinine clearance (Ccr))

Exclusion Criteria:

1. History of drug hypersensitivity.
2. Contraindication of oral S-1 administration (refer appended paper).
3. Serious surgical or non-surgical complications
4. Active secondary cancer.
5. Watery diarrhea.
6. Pregnant or lactating women.
7. Male who has intention to make pregnant
8. Patient to whom primary doctor judged inadequate to register.

Primary outcomes:
measure: Completion rate
timeFrame: One year
Secondary outcomes:
measure: Incidence and grade of adverse reactions
timeFrame: One year
Other outcomes:
Locations:
city: Nagasaki
country: Japan
facility: Division of Surgical Oncology, Nagasaki University Graduate School of BIomedical Sciences
Study officials:
affiliation: Division of Surgical Oncology, Department of Translational Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences
name: Takeshi Nagayasu, MD. PhD.
role: STUDY_CHAIR
References:
Clinical trial NCT00998985: A Study of Grazoprevir (MK-5172) in Hepatitis C-Infected Male Participants (MK-5172-004)
Official title: A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Grazoprevir (MK-5172) in Hepatitis C Infected Male Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Hepatitis C
Lead sponsor: Merck Sharp & Dohme LLC
Sponsor class: INDUSTRY
First posted: 2009-10-21
Enrollment: 91
Sex: MALE
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This multiple dose study will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of grazoprevir (MK-5172) in Genotype (GT) 1 and GT3 Hepatitis C virus (HCV)- infected participants. The primary hypothesis is that administration of grazoprevir for 7 days is sufficiently safe and well tolerated in HCV-infected males.


Eligibility criteria: Inclusion Criteria:

* Baseline health is stable.
* Has a clinical diagnosis of chronic HCV infection.

Exclusion Criteria:

* Has a history of stroke or chronic seizures.
* Has a history of cancer.
* Has a history of human immunodeficiency virus (HIV) infection.
* Has had major surgery, donated blood or participated in another investigational study within the past 3 months.

Primary outcomes:
measure: Number of Participants With Clinical and Laboratory Adverse Events (AEs)
timeFrame: All AEs: 15 Days after last dose; Serious AEs (SAEs) up to 2 months after last dose (Up to 67 days)
Secondary outcomes:
measure: Area Under the Curve for 0 to 24 Hours Post-dose (AUC[0-24hr]) of Grazoprevir on Day 7
timeFrame: Day 7 at the following time points: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, and 24 hours post-dose
measure: 24 Hour Plasma Concentration (C[24hr]) of Grazoprevir on Day 7
timeFrame: Day 7 at 24 hours post-dose
measure: Maximum log10 HCV RNA Reduction From Baseline Following Administration of Grazoprevir in Participants With GT1 HCV or Pooled GT1 and GT3 HCV Participants Treated With Placebo
timeFrame: Baseline and up to approximately 2 months
measure: Maximum log10 HCV RNA Reduction From Baseline Following Administration of Grazoprevir in Participants With GT3 HCV or Pooled GT1 and GT3 HCV Participants Treated With Placebo
timeFrame: Baseline and up to approximately 2 months
Other outcomes:
Locations:
Study officials:
affiliation: Merck Sharp & Dohme LLC
name: Medical Director
role: STUDY_DIRECTOR
References:
citation: Yeh WW, Fraser IP, Jumes P, Petry A, Lepeleire I, Robberechts M, Reitmann C, Van Dyck K, Huang X, Guo Z, Panebianco D, Nachbar RB, O'Mara E, Wagner JA, Butterton JR, Dutko FJ, Moiseev V, Kobalava Z, Huser A, Visan S, Schwabe C, Gane E, Popa S, Ghicavii N, Uhle M, Wagner F. Antiviral Activity, Safety, and Tolerability of Multiple Ascending Doses of Elbasvir or Grazoprevir in Participants Infected With Hepatitis C Virus Genotype-1 or -3. Clin Ther. 2018 May;40(5):704-718.e6. doi: 10.1016/j.clinthera.2018.03.002. Epub 2018 Apr 25.
Clinical trial NCT05478356: The Effects of Low-dose Atropine and Orthokeratology in Pediatric Myopia Control
Official title: The Effects of Low-dose Atropine and Orthokeratology in Pediatric Myopia Control
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Myopia
Lead sponsor: Evidence Based Cataract Study Group
Sponsor class: OTHER
First posted: 2022-07-28
Enrollment: 100
Sex: ALL
Minimum age (years): 8
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Both orthokeratology and atropine eye drops are effective methods for myopia control, but few studies have compared them all together simultaneously. Therefore, the primary aim of the present study was to compare the effect of orthokeratology versus low-dose (0.01% and 0.02%) atropine on the control of myopia progression.


Eligibility criteria: Inclusion Criteria:

Best corrected visual acuity less then 0.00 log MAR (minimum angle of resolution) units Cycloplegic SER of - 1.0 D or less in both eyes. An inter-eye cycloplegic SER difference of 1.00 D or more.

Exclusion Criteria:

Children with cycloplegic cylinder refraction of more than + 1.00 D or less than - 1.00 D.

History of binocular vision problems, including strabismus. History of known ocular disorders, including media opacities, macular dysgenesis, optic nerve hypoplasia, perinatal brain injury, buphthalmos, and retinopathy of prematurity.

History of medication use that might have affected the refractive results. Systemic or developmental problems that might have hindered refractive development.

Primary outcomes:
measure: Progression of myopia
timeFrame: 1 year
measure: Progression of axial length
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Beijing
country: China
facility: Visionly Eye Hospital
state: Beijing
city: Shanghai
country: China
facility: Parkway Hospital
state: Shanghai
Study officials:
References:
Clinical trial NCT01973556: Pharmacist-Physician Collaborative Medication Therapy Management Services (MTMS) Demonstration Project
Official title: Pharmacist-Physician Collaborative Medication Therapy Management Services (MTMS) Demonstration Project
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hypertension
Lead sponsor: University of California, San Diego
Sponsor class: OTHER
First posted: 2013-10-31
Enrollment: 75
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: Patients managed by a newly formed pharmacist-physician medication therapy management team in a university primary care clinic will have better blood pressure control than patients receiving usual care.


Eligibility criteria: Inclusion Criteria:

* age 18 years or over
* diagnosis of hypertension with most recent blood pressure \>140/90 mmHg or blood pressure \>130/80 mmHg if patients also had diabetes mellitus
* treated with at least one anti-hypertensive medication
* continuous active patient (at least one visit) of the clinic for at least the past 6 months (1/1/2010-6/31/2010)
* English speaking
* Able to complete questionnaires in English.

Exclusion Criteria:

-do not meet provisions of the clinical collaborative agreement protocol in the judgment of the patient's physician or the clinical pharmacist

Primary outcomes:
measure: systolic blood pressure
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: La Jolla
country: United States
facility: University of California San Diego
state: California
Study officials:
References:
citation: Hirsch JD, Steers N, Adler DS, Kuo GM, Morello CM, Lang M, Singh RF, Wood Y, Kaplan RM, Mangione CM. Primary care-based, pharmacist-physician collaborative medication-therapy management of hypertension: a randomized, pragmatic trial. Clin Ther. 2014 Sep 1;36(9):1244-54. doi: 10.1016/j.clinthera.2014.06.030. Epub 2014 Jul 30.
Clinical trial NCT00409656: Prospective, Randomized Trial of Basiliximab (Simulect) in the Prophylaxis of High-Risk Keratoplasty Patients
Official title: Prospective, Randomized Trial of Basiliximab (Simulect) in the Prophylaxis of High-Risk Keratoplasty Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Corneal Transplantation
Lead sponsor: University Hospital Freiburg
Sponsor class: OTHER
First posted: 2006-12-11
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Most high risk keratoplasties are currently performed under systemic immunosuppression. Immunosuppressants are currently either Cyclosporine A or mycophenolate mofetile, administered for around 6 months. Due to potentially severe adverse effects, new immunosuppressive exerting less side effects would be desirable. Basiliximab is a monoclonal, chimeric antibody, targeted specifically against the Interleukin-2-Rezeptor from activated T-cells. This agent is known to specifically inhibit T-cell proliferation upon intravenous application only twice following transplantation. Basiliximab has already been demonstrated effective in kidney transplantation.

This investigation is a prospective, randomized clinical trial on orthotopic, high-risk penetrating keratoplasty. Basiliximab is evaluated against systemic Cyclosporine A. Primary endpoint is graft rejection. Secondary endpoint is clear graft survival.


Eligibility criteria: Inclusion Criteria:

* high risk keratoplasty

Exclusion Criteria:

* normal risk keratoplasty

Primary outcomes:
measure: Graft rejection
Secondary outcomes:
measure: Clear graft survival
Other outcomes:
Locations:
Study officials:
affiliation: University Eye Hospital, Freiburg
name: Thomas Reinhard, MD, Prof.
role: STUDY_DIRECTOR
References:
citation: Abudou M, Wu T, Evans JR, Chen X. Immunosuppressants for the prophylaxis of corneal graft rejection after penetrating keratoplasty. Cochrane Database Syst Rev. 2015 Aug 27;2015(8):CD007603. doi: 10.1002/14651858.CD007603.pub2.
Clinical trial NCT01571856: Efficacy of Use of Zinc in the Treatment of Acute Diarrhea in Infants
Official title: Efficacy of Use of Zinc in the Treatment of Acute Diarrhea in Infants Under Six Months.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Acute Diarrhea
Acute Gastroenteritis
Keywords: Acute Diarrhea
Zinc
Children
Lead sponsor: Centro Pediatrico Albina de Patino
Sponsor class: OTHER
First posted: 2012-04-05
Enrollment: 52
Sex: ALL
Minimum age (years): 1
Maximum age (years): 6
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine the effect of zinc in acute watery diarrhea in children. The investigators will evaluate the effect of product versus placebo.

Detailed description: Background: Acute Gastroenteritis is one of the most and frequent disease in the childhood, today exist strong evidence of beneficial effect of use of zinc in acute diarrhea in children over 6 months. but there are not enough clinical trials to show this beneficial effect on children under 6 months.

Objectives: To evaluate the effect of zinc in the treatment of children under 6 months age with acute diarrhea.

Methods: A randomized clinical trial, controlled, double-blind. The investigators will have two groups of patients : One group will receive zinc plus oral rehydration and the other one will receive placebo plus oral rehydration; the parameters of evaluation are going to be the duration of diarrheal episode, number of diarrhea stools by day, weight of stool, nutritional state.

Eligibility criteria: Inclusion Criteria:

* all acute diarrhea

Exclusion Criteria:

* Severe malnourishment
* Severe dehydration
* Systemic infections
* coinfections

Primary outcomes:
measure: duration of diarrheal episode
timeFrame: five days
Secondary outcomes:
measure: duration of hospitalization
timeFrame: 5 days
measure: weight of stool
timeFrame: 5 days
Other outcomes:
Locations:
city: Cochabamba
country: Bolivia
facility: Centro Pediatrico Albina Patino
Study officials:
affiliation: Centro Pediatrico Albina de Patino
name: Giuseppe Grandy, MD MSc
role: STUDY_DIRECTOR
affiliation: Centro Pediatrico Albina Ptino
name: Zaida Cama, MD
role: STUDY_CHAIR
References:
Clinical trial NCT01159756: To Assess the Safety and Efficacy of Travacom in Patients With Uncontrolled Intraocular Pressure
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Uncontrolled Intraocular Pressure
Keywords: Travacom
Glaucoma
Travoprost
Timolol
Lead sponsor: Alcon Research
Sponsor class: INDUSTRY
First posted: 2010-07-09
Enrollment: 468
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study is a multi-site, unmasked phase IV study. Travacom(R) is a combination topical ocular agent, containing travoprost and timolol, which lower intraocular pressure (IOP) by complementary mechanisms of action. The safety and efficacy of both travoprost and timolol have been established as single and adjunctive therapy in well-controlled clinical studies in thousands of patients diagnosed with open angle glaucoma (OAG) or ocular hypertension. The objective of this study is to assess the safety and efficacy of changing to Travacom from prior pharmacotherapy in uncontrolled patients with open-angled glaucoma or ocular hypertension across India.


Eligibility criteria: Inclusion Criteria:

* Must have a clinical diagnosis of ocular hypertension, primary open-angle or pigment dispersion glaucoma in both eyes.
* Must be willing to discontinue the use of all other ocular hypotensive medications prior to receiving the study medication for the entire course of the study.
* Must be able to follow instructions and be willing and able to attend all study visits.

Exclusion Criteria:

* A known medical history of allergy, hypersensitivity or poor tolerance to any component of Travacom that is deemed clinically significant in the opinion of the Principle Investigator.
* Any abnormality preventing reliable applanation tonometer in either eye. Corneal dystrophies.
* Any opacity or subject uncooperativeness that restricts adequate examination of the ocular fundus or anterior chamber of either eye.

Primary outcomes:
measure: Primary efficacy: Change in IOP at the final visit from prior beta-blocker monotherapy (Timolol 0.5% only)
timeFrame: Baseline to Visit 3 (Week 6-8)
measure: Safety: Adverse Events.
timeFrame: Baseline to Visit 3 (Week 6-8)
measure: Secondary efficacy: Percentage of subjects at target IOP (</ 18 mmHg), regardless of prior therapy.
timeFrame: Baseline to Visit 3 (Week 6-8)
Secondary outcomes:
Other outcomes:
Locations:
city: Kolkata
country: India
facility: Disha Eye Hospitals
Study officials:
References:
Clinical trial NCT03616756: Authentic Connections for Nurse Leaders
Official title: Fostering Resilience Amongst Mothers Under Stress: Authentic Connections for Nurse Leaders
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Stress
Keywords: Nurse leader
Resilience
Parenting
Stress
Depression
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
Collaborators: name: Arizona State University
First posted: 2018-08-06
Enrollment: 24
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this pilot study is to test the feasibility and outcomes of a supportive group-based intervention, Authentic Connections, to be used for nurse leaders at Mayo Clinic, Rochester, in a collaboration involving faculty at Arizona State University (ASU) Department of Psychology, Dr. Sunyia Luthar.


Eligibility criteria: * In an Nursing Education Specialist (NES) or Clinical Nurse Specialist (CNS) nurse leader role at Mayo Clinic Rochester
* Female gender
* A mother to at least one child or adult child

Primary outcomes:
measure: Connor-Davidson Resilience Scale - 2 item
timeFrame: Baseline
measure: Connor-Davidson Resilience Scale - 2 item
timeFrame: 12 weeks
measure: Connor-Davidson Resilience Scale - 2 item
timeFrame: 24 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Scottsdale
country: United States
facility: Mayo Clinic in Arizona
state: Arizona
city: Jacksonville
country: United States
facility: Mayo Clinic in Florida
state: Florida
city: Rochester
country: United States
facility: Mayo Clinic in Rochester
state: Minnesota
Study officials:
affiliation: Mayo Clinic
name: Sherry S Chesak
role: PRINCIPAL_INVESTIGATOR
References: